Subscribe To
GANX / Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs
Content Topics
Gain
Therapeutics
Posts
Encouraging
Preclinical
Data
From
Parkinson s
Alzheimer s
Programs
Stock
GANX
GANX News
By InvestorPlace
October 4, 2023
Why Is Gain Therapeutics (GANX) Stock Moving Today?
Gain Therapeutics (NASDAQ: GANX ) stock is on the move Wednesday as investors react to updated clinical trial news from the company. According to a p more_horizontal
By GlobeNewsWire
September 25, 2023
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
BETHESDA, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the disc more_horizontal
By Zacks Investment Research
August 10, 2023
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Misses Revenue Estimates
Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares more_horizontal
By Zacks Investment Research
May 12, 2023
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Tops Revenue Estimates
Gain Therapeutics, Inc. (GANX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares more_horizontal
By GlobeNewsWire
March 29, 2023
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer's disease more_horizontal
By Zacks Investment Research
May 16, 2022
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numb more_horizontal
By Benzinga
March 15, 2022
Gain Therapeutics Posts Encouraging Preclinical Data From Parkinson's, Alzheimer's Programs
Gain Therapeutics Inc (NASDAQ: GANX) has presented new preclinical data from its Parkinson's and Alzheimer's Disease programs. These results were more_horizontal